Ticker Details
Fate Therapeutics, Inc. Fate Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders.
IPO Date:	October 1, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$279.18M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.59 | 4.00%
Avg Daily Range (30 D):	$0.10 | 3.69%
Avg Daily Range (90 D):	$0.12 | 5.70%

Institutional Daily Volume
Avg Daily Volume:	.98M
Avg Daily Volume (30 D):	1.99M
Avg Daily Volume (90 D):	3.05M

Trade Size
Avg Trade Size (Sh.):	124
Avg Trade Size (Sh.) (30 D):	183
Avg Trade Size (Sh.) (90 D):	245

Institutional Trades
Total Institutional Trades:	3,498
Avg Institutional Trade:	$2.73M
Avg Institutional Trade (30 D):	$1.18M
Avg Institutional Trade (90 D):	$1.52M
Avg Institutional Trade Volume:	.14M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.78M
Avg Closing Trade (30 D):	$.79M
Avg Closing Trade (90 D):	$2.07M
Avg Closing Volume:	211.86K

News

Jun 10, 2026 @ 5:00 PM Lupus Nephritis Clinical Trial Landscape Becomes I... Source: Delveinsight

May 20, 2026 @ 1:50 PM Cell-Based Therapies Poised to Disrupt Multi-Billi... Source: Market News Updates

Mar 27, 2026 @ 1:15 PM Scalable Biotech Manufacturing Unlocks a $14B Mark... Source: Usanewsgroup.Com News Commentary

Mar 3, 2026 @ 3:02 PM Cell Therapies Moving From Lab to Factory Floor, a... Source: Prnewswire

Feb 16, 2026 @ 6:00 PM IPSC-derived NK Cells Clinical Trial Pipeline Gain... Source: Delveinsight

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-1.05	$-.25	$-.26
Diluted EPS	$-1.05	$-.25	$-.26
Revenue	$6.49M	$2.08M	$1.3M
Gross Profit
Net Income / Loss	$-126M	$-30.16M	$-31.21M
Operating Income / Loss	$-133.59M	$-31.13M	$-33M
Cost of Revenue
Net Cash Flow	$-9M	$-23.4M	$M
PE Ratio